# Mobidiag and Autobio form joint venture for Novodiag platform in China

Mobidiag and Autobio Diagnostics formed a joint venture to commercialise the Novodiag platform in China, with a total investment of €12.3 million. Mobidiag holds 35% and Autobio 65%.

- Type: Partnership
- Announced: 2018-12-18
- Where: China, China
- Value: $14.0M (12.3M EUR)
- Status: announced
- Products: Novodiag platform, diagnostic assays for respiratory, gastroenteric infections, meningitis
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Mobidiag](https://endata.com/companies/36258.md) (partner)
- [Autobio Diagnostics](https://endata.com/companies/36259.md) (partner)

## Sources

- [medicaldevice-network.com](https://www.medicaldevice-network.com/news/mobidiag-autobio-jv/), 2018-12-18: "Finnish molecular diagnostics developer Mobidiag has signed an agreement with Chinese clinical diagnostics company Autobio Diagnostics to form a joint venture (JV) firm to commercialise its Novodiag platform in China."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.